



# Changes in Near-Infrared Spectroscopy After Congenital Cyanotic Heart Surgery

Judith Ju-Ming Wong<sup>1,2\*</sup>, Ching Kit Chen<sup>3</sup>, Rajesh Babu Moorakonda<sup>4,5</sup>, Olivia Wijeweera<sup>6</sup>, Tracy Yi Shuen Tan<sup>6</sup>, Masakazu Nakao<sup>7</sup>, John Carson Allen Jr.<sup>5</sup>, Tsee Foong Loh<sup>1,2</sup> and Jan Hau Lee<sup>1,2</sup>

<sup>1</sup> Children's Intensive Care Unit, Department of Paediatric Subspecialties, KK Women's and Children's Hospital, Singapore, Singapore, <sup>2</sup>Duke-NUS Medical School, Singapore, Singapore, <sup>3</sup>Cardiology Services, Department of Paediatric Subspecialties, KK Women's and Children's Hospital, Singapore, Singapore, <sup>4</sup>Singapore Clinical Research Institute, Singapore, Singapore, <sup>5</sup>Duke-NUS Medical School, Centre for Quantitative Medicine, Singapore, Singapore, <sup>6</sup>Department of Paediatric Anaesthesia, KK Women's and Children's Hospital, Singapore, Singapore, <sup>7</sup>Department of Paediatric Cardiothoracic Surgery, KK Women's and Children's Hospital, Singapore, Singapore

**Background:** Since oxygen saturation from pulse oximetry (SpO<sub>2</sub>) and partial pressure of arterial oxygen (PaO<sub>2</sub>) are observed to improve immediately after surgical correction of cyanotic congenital heart disease (CHD), we postulate that cerebral (CrO<sub>2</sub>) and somatic (SrO<sub>2</sub>) oximetry also improves immediately post-correction. We aim to prospectively examine CrO<sub>2</sub> and SrO<sub>2</sub>, before, during, and after surgical correction as well as on hospital discharge in children with cyanotic CHD to determine if and when these variables increase.

### **OPEN ACCESS**

#### Edited by:

Utpal S. Bhalala, Baylor College of Medicine, United States

#### Reviewed by:

Meena Nathan, Boston Children's Hospital, Harvard University, United States Arun Bansal, Post Graduate Institute of Medical Education and Research, India

#### \*Correspondence:

Judith Ju-Ming Wong judith.wong.jm@singhealth.com.sg

#### Specialty section:

This article was submitted to Pediatric Cardiology, a section of the journal Frontiers in Pediatrics

Received: 08 December 2017 Accepted: 26 March 2018 Published: 13 April 2018

#### Citation:

Wong JJ-M, Chen CK, Moorakonda RB, Wijeweera O, Tan TYS, Nakao M, Allen JC Jr., Loh TF and Lee JH (2018) Changes in Near-Infrared Spectroscopy After Congenital Cyanotic Heart Surgery. Front. Pediatr. 6:97. doi: 10.3389/fped.2018.00097 **Methods:** This is a prospective observational trial. Eligibility criteria included children below 18 years of age with cyanotic CHD who required any cardiac surgical procedure. CrO<sub>2</sub> and SrO<sub>2</sub> measurements were summarized at six time-points for comparison: (1) pre-cardiopulmonary bypass (CPB); (2) during CPB; (3) post-CPB; (4) Day 1 in the pediatric intensive care unit (PICU); (5) Day 2 PICU; and (6) discharge. Categorical and continuous variables are presented as counts (percentages) and median (interquartile range), respectively.

**Results:** Twenty-one patients were analyzed. 15 (71.4%) and 6 (28.6%) patients underwent corrective and palliative surgeries, respectively. In the corrective surgery group, SpO<sub>2</sub> increased immediately post-CPB compared to pre-CPB [99 (98, 100) vs. 86% (79, 90); p < 0.001] and remained in the normal range through to hospital discharge. Post-CPB CrO<sub>2</sub> did not change from pre-CPB [72.8 (58.8, 79.0) vs. 72.1% (63.0, 78.3); p = 0.761] and even decreased on hospital discharge [60.5 (53.6, 62.9) vs. 72.1% (63.0, 78.3); p = 0.005]. Post-CPB SrO<sub>2</sub> increased compared to pre-CPB [87.3 (77.2, 89.5) vs. 72.7% (65.6, 77.3); p = 0.001] but progressively decreased during PICU stay to a value lower than baseline at hospital discharge [66.9 (57.3, 76.9) vs. 72.7% (65.6, 77.3); p = 0.048].

**Conclusion:** CrO<sub>2</sub> and SrO<sub>2</sub> did not increase after corrective surgery of cyanotic CHD even up to hospital discharge. Future larger studies are required to validate these findings. (This study is registered with ClinicalTrials.gov ID: NCT02417259.)

Keywords: congenital heart disease, congenital heart surgery, children, near-infrared spectroscopy, perioperative care, pediatric, regional oximetry

1

# INTRODUCTION

Adoption of near-infrared spectroscopy (NIRS) is increasing in pediatric cardiac anesthesia and pediatric intensive care units (PICUs) across North America and Europe (1). The two most common sites for regional NIRS are cerebral ( $CrO_2$ ) and somatic ( $SrO_2$ ) oximetry. Proposed utility of NIRS include: (1) pre-operative risk stratification; (2) monitoring for uncommon events; and (3) guide physiologic interventions (2). However, significant debate remains on the interpretation of NIRS monitoring because of the lack of universally accepted normal/abnormal values, definition of a threshold event and standardized management algorithm (1, 3).

Despite current limitations, cerebral oximetry has been validated with other regional oxygenation measures (e.g., jugular venous bulb saturations, superior vena cava saturations) and global oxygenation measures (e.g., serum lactate, mixed venous saturations) (4-6). Associations between low NIRS and poor long-term neurological outcomes (e.g., neurodevelopmental scales, magnetic resonance imaging changes) have been reported (7, 8). Conversely, however, there are also studies reporting failure of NIRS to correlate with oxygenation measures or clinical outcomes (9). Moreover, the natural history of tissue oximetry over a longitudinal perioperative period in children with congenital heart disease (CHD), especially those with cyanotic CHD undergoing cardiac surgery is not well studied. Early studies reported conflicting data as to whether baseline CrO<sub>2</sub> was decreased in patients with cyanotic and acyanotic CHD (10, 11). There is sparse longitudinal data across the perioperative period (12).

Since oxygen saturations from pulse oximetry  $(SpO_2)$  and partial pressure of arterial oxygen  $(PaO_2)$  are observed to improve immediately after surgical correction of cyanotic CHD, we postulate that  $CrO_2$  and somatic  $(SrO_2)$  oximetry would also improve immediately post-correction. Therefore, we undertook this pilot study to examine  $CrO_2$  and  $SrO_2$ , before, during and after surgical correction as well as on hospital discharge in these children to determine if and when these variables increase.

# MATERIALS AND METHODS

### **Patients**

This prospective observational study was approved by the Centralized Institutional Review Board of our hospital. Both parental informed and written consent was obtained and patients were enrolled between July 2015 and June 2016 at KK Women's and Children's Hospital, Singapore. Eligibility criteria included patients below 18 years of age with cyanotic CHD who required any cardiac surgical procedure. These surgeries can be either full corrective or staged procedures. Exclusion criteria included

premature infants of less than a corrected age of 35 weeks and congenital lactic acidosis syndromes.

### **Anesthesia and Perfusion Methods**

The anesthesia induction technique was at the discretion of the attending anesthetist. Inhaled anesthetic used was sevoflurane. Intravenous agents included morphine, fentanyl, ketamine, midazolam, propofol, rocuronium, and dexmedetomidine. After induction of anesthesia, standard monitoring included: central venous catheter in the right or left internal jugular vein for central venous pressure monitoring; radial or femoral artery catheter for measurement of systemic arterial blood pressure; indwelling urinary catheter for monitoring urinary output and; esophageal/nasopharyngeal and rectal temperature probes to measure core body temperature. Core cooling was achieved through the cardiopulmonary bypass (CPB) circuit. The bypass circuit was primed with packed cells. Pump flow rates were maintained at 100-150 ml/kg/min to achieve mean arterial pressure of 30-55 mmHg. Deep hypothermic circulatory arrest (DHCA) to 18°C was used at the discretion of the surgeon. Modified ultrafiltration was performed in infants and patients below 10 kg after CPB.

### **Regional Oxygen Saturation Monitoring**

The use of  $CrO_2$  and  $SrO_2$  in patients undergoing cardiac surgery is not routine at our center. During the study,  $CrO_2$  and  $SrO_2$  were measured in the context of a prospective observational study and not for clinical purposes.

Regional oxygen saturation was measured using the Medtronic INVOS 5100C, Boulder, CO, USA. Two site recording from CrO<sub>2</sub> and SrO<sub>2</sub> regions were performed before induction of anesthesia. The cerebral sensor was placed over the left or right forehead midway between the eyebrow and hairline and the somatic sensor was placed over the left or right flank at T12-L2 vertebral level. After a short period to allow for adjustments to obtain good contact, the baseline tissue oxygenation was recorded. In children who were fretful and uncooperative, the probes were placed and baseline recorded soon after induction of anesthesia. Subsequently, data were collected and downloaded to a storage device every 6 s throughout the surgery and for 48 h from admission to the PICU. A pre-discharge recording was made just prior to hospital discharge-this was done over a period of 4-6 h while the patient was asleep. If the hospital discharge was delayed the pre-discharge recording was taken whenever the attending cardiologist deemed the patient medically fit for discharge.

# **Data Extraction**

Intraoperative clinical data were extracted from important time-points such as time of induction, median sternotomy, start and end of CPB, aortic clamp and unclamp, and end of surgery. Clinical and laboratory variables (e.g., heart rate, arterial blood pressure, central venous pressure, temperature, urine output, arterial blood gases, and serum lactate) were measured and recorded as per routine practice in the operating theater and PICU. Acute kidney injury was defined according to the RIFLE criteria. Including those who were at Risk of kidney injury ( $\geq 1.5 \times$  baseline creatinine or urine output <0.5 ml/kg/h) (13).

Abbreviations: CaO<sub>2</sub>, arterial oxygen content; CBF, cerebral blood flow; cFOE, cerebral fractional oxygen extraction; CHD, congenital heart disease; CPB, cardiopulmonary bypass; CRMO<sub>2</sub>, cerebral metabolic rate of oxygen; CrO<sub>2</sub>, cerebral oximetry; DHCA, deep hypothermic circulatory arrest; NIRS, near-infrared spectroscopy; PaO<sub>2</sub>, partial pressure of arterial oxygen; PICU, pediatric intensive care unit; SpO<sub>2</sub>, pulse oximetry; SrO<sub>2</sub>, somatic oximetry; SvO<sub>2</sub>, cerebral venous oxygenation.

### **Statistical Analysis**

Cerebral oximetry and SrO<sub>2</sub> data were captured electronically every 6 s. These were summarized into medians [interguartile ranges (IQR)] for six time-points for comparison: (1) pre-CPB (from time of application of NIRS sensors before induction of anesthesia to time of CPB initiation); (2) on CPB (from time of initiation to end CPB); (3) post-CPB (from time of end CPB to transfer out from operating theater); (4) Day 1 PICU (from time of PICU admission for 24 h); (5) Day 2 PICU (from 24 to 48 h of PICU admission); and (6) discharge (4-6 h overnight prior to day of anticipated discharge). Categorical data were presented as counts and percentages. Continuous data were presented as medians and IQR. Differences between categorical variables were analyzed using the Fisher's exact test. Differences between continuous variables were analyzed using the Wilcoxon's signed rank test. Statistical analysis was performed using SAS 9.4 for Windows (SAS Institute Cary, NC, USA). All statistical tests were two-tailed, and the significance level was taken as p < 0.05.

# RESULTS

A total of 24 children with cyanotic CHD underwent surgery over the 1-year study period and all were approached for consent. Parents of two children declined to participate in the study and parents of another child withdrew consent after enrollment (**Figure 1**). The overall median age was 18.1 (7.8, 51.4) months (**Table 1**). Fifteen [15/21 (71.4%)] children underwent corrective surgeries. The most common surgery was repair of tetralogy of Fallot [7/21 (33.3%)] followed by the Fontan procedure [3/21 (14.3%)] (**Table 2**). The median CPB and aortic cross-clamp times were 187.5 (113.0, 263.5) and 80.0 (37.0, 133.0) minutes, respectively (**Table 2**). Only one patient (Norwood procedure) required total circulatory arrest (duration 77 min). Intraoperatively, adrenaline [20/21 (95.2%)] and milrinone [18/21 (85.7%)] were the most frequently used inotropes.

All patients remained on mechanical ventilation on arrival to the PICU. Five [5/21 (23.8%)] were extubated within several hours of admission and 9/21 (42.9%) on postoperative day 1. The median duration of mechanical ventilation was 21.0 (13.0, 92.0) hours. Twenty [20/21 (95.3%)] patients required inotropic support on PICU admission. The most common inotrope used was milrinone [18/20 (90.0%)], followed by adrenaline [17/20 (85.0%)] (Table 3). Median lactate levels within the first 24 h was 2.7 (2.3, 5.0) mmol/L. Significant hemodynamic events occurred in 17/21 (80.9%) patients with the most common being hypotension [14/21 (66.7%)] (Table 4). Fluid bolus was required more frequently in the corrective surgery group in the first day of PICU compared to the second day [12/15 (80.0%) vs. 4/15 (33.3%); p = 0.022]. Acute kidney injury occurred in 17/21 (81.0%) patients. However, only one (5.6%) patient required renal replacement therapy. 3/21 patients required veno-arterial extracorporeal membrane oxygenation postoperatively, of whom 1/3 (33.3%) survived. Overall PICU mortality was 2/21 (9.5%). The causes of death in these two patients were necrotizing enterocolitis and hypoplastic left heart syndrome.

In the corrective surgery group, SpO<sub>2</sub> increased immediately post-CPB compared to pre-CPB [99 (98, 100) vs. 86% (79, 90); p < 0.001] and remained in the normal range through to hospital discharge [97% (92, 98)] (**Table 5**). Post-CPB CrO<sub>2</sub> did not change from pre-CPB [72.8 (58.8, 79.0) vs. 72.1% (63.0, 78.3); p = 0.761]. Postoperative day 2 CrO<sub>2</sub> was also not different from pre-CPB [68.3 (55.0, 74.4) vs. 72.1% (63.0, 78.3); p = 0.520]. On hospital discharge, however, CrO<sub>2</sub> was lower than baseline (pre-CPB) [60.5 (53.6, 62.9) vs. 72.1% (63.0, 78.3); p = 0.005]. Of note, the majority of our patients [11/21 (52.4%)] had their baseline (pre-CPB) taken a few minutes after intubation and ventilation.

Post-CPB SrO<sub>2</sub> increased compared to pre-CPB [87.3 (77.2, 89.5) vs. 72.7% (65.6, 77.3); *p* < 0.001] but progressively



#### **TABLE 1** | Summary of patient characteristics (N = 21).

| Patient characteristics          | Corrective surgery ( $N = 15$ ) | Non-corrective surgery ( $N = 6$ ) | All patients ( $N = 21$ ) |
|----------------------------------|---------------------------------|------------------------------------|---------------------------|
| Age, months                      | 18.7 (10.3, 51.4)               | 8.0 (0.4, 46.0)                    | 18.1 (7.8, 51.4)          |
| Weight, kg                       | 10.5 (7.0, 14.1)                | 6.0 (3.0, 11.4)                    | 8.5 (5.4, 13.5)           |
| Male gender                      | 6 (40.0)                        | 3 (50.0)                           | 9 (42.9)                  |
| Ethnicity                        |                                 |                                    |                           |
| Chinese                          | 8 (53.3)                        | 3 (50.0)                           | 11 (52.4)                 |
| Malay                            | 1 (6.7)                         | 2 (33.3)                           | 3 (14.3)                  |
| Indian                           | 1 (6.7)                         | 0 (0.0)                            | 1 (4.8)                   |
| Others                           | 5 (33.3)                        | 1 (16.7)                           | 6 (28.6)                  |
| Comorbidities                    | 3 (20.0)                        | 2 (33.3)                           | 5 (23.8)                  |
| RACHS score                      |                                 |                                    |                           |
| 1                                | O (O)                           | O (O)                              | O (O)                     |
| 2                                | 9 (60.0)                        | 4 (66.7)                           | 13 (61.9)                 |
| 3                                | 6 (40.0)                        | O (O)                              | 6 (28.6)                  |
| 4                                | O (O)                           | 1 (16.7)                           | 1 (4.8)                   |
| 5                                | O (O)                           | O (O)                              | O (O)                     |
| 6                                | O (O)                           | 1 (16.7)                           | 1 (4.8)                   |
| STAT category                    |                                 |                                    |                           |
| 1                                | 0 (0.0)                         | 0 (0.0)                            | 0 (0.0)                   |
| 2                                | 12 (80.0)                       | 3 (50.0)                           | 15 (71.4)                 |
| 3                                | 2 (13.3)                        | 1 (16.7)                           | 3 (14.3)                  |
| 4                                | 1 (6.7)                         | 1 (16.7)                           | 2 (9.5)                   |
| 5                                | 0 (0.0)                         | 1 (16.7)                           | 1 (4.8)                   |
| PIM 3                            | 0.1 (0.1, 0.2)                  | 0.2 (0.1, 0.7)                     | 0.1 (0.1, 0.2)            |
| PELOD 2                          | 7.0 (5.0, 11.0)                 | 5.5 (2.0, 9.0)                     | 7.0 (5.0, 10.0)           |
| Cardiopulmonary bypass time, min | 193.0 (134.0, 269.0)            | 121.0 (82.0, 243.0)                | 187.5 (113.0, 263.5)      |
| Aortic cross-clamp time, min     | 110.0 (65.0, 171.0)             | 33.0 (27.0, 34.0)                  | 80.0 (37.0, 133.0)        |
| Duration of surgery, min         | 335.0 (281.0, 428.0)            | 360.5 (263.0, 497.0)               | 354.0 (281.0, 428.0)      |
| Intraoperative adrenaline        | 14 (93.3)                       | 6 (100.0)                          | 20 (95.2)                 |
| Intraoperative milrinone         | 14 (93.3)                       | 4 (66.7)                           | 18 (85.7)                 |
| Acute kidney injury              | 12 (80.0)                       | 5 (83.3)                           | 17 (81.0)                 |
| PICU mortality                   | 1 (6.7)                         | 1 (16.7)                           | 2 (9.5)                   |
| ECMO                             | 1 (6.7)                         | 2 (33.3)                           | 3 (14.3)                  |
| Length of PICU stay, days        | 2.0 (1.0, 6.0)                  | 2.0 (1.0, 7.0)                     | 2.0 (1.0, 6.0)            |
| Length of hospital stay, days    | 10.0 (8.0, 21.0)                | 12.0 (5.0, 100.0)                  | 10.0 (8.0, 21.0)          |

Categorical and continuous variables presented as counts (percentages) and median (interquartile range), respectively.

PELOD, pediatric logistic organ dysfunction; PIM, Pediatric Index of Mortality; PICU, pediatric intensive care unit; RACHS, risk adjustment for congenital heart surgery, STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery; ECMO, extracorporeal membrane oxygenation.

decreased during PICU stay to a value lower than baseline at hospital discharge [66.9 (57.3, 76.9) vs. 72.7% (65.6, 77.3); p = 0.048]. The aggregate SpO<sub>2</sub>, CrO<sub>2</sub>, and SrO<sub>2</sub> trend for patients who underwent corrective surgery are shown in **Figures 2–4**. There were no significant changes in SpO<sub>2</sub>, CrO<sub>2</sub>, and SrO<sub>2</sub> in the palliative surgery group from baseline, postoperatively and on discharge.

### DISCUSSION

We prospectively studied a small cohort of 21 children with cyanotic CHD and characterized their  $CrO_2$  and  $SrO_2$  longitudinally over the perioperative period. Unlike  $SpO_2$  which normalized immediately after corrective surgery,  $CrO_2$  did not increase after surgical correction of cyanotic CHD even up to the time of hospital discharge.  $SrO_2$  showed a transient increment during and after CPB but decreased subsequently.

Arterial oxygen saturation measured by  $SpO_2$  increases after surgical correction of cyanotic CHD.  $CrO_2$ , measuring the concentration of hemoglobin and oxy-hemoglobin in arterioles, capillaries and venules reflects cerebral tissue oxygenation which is taken as a surrogate of cerebral venous oxygenation (SvO<sub>2</sub>) (14, 15). In this observational study, the CrO<sub>2</sub> remains the same. This seems to suggest that cerebral fractional oxygen extraction (cFOE) [cFOE =  $(SaO_2 - SvO_2)/SaO_2$ ] increased during the post-surgical repair period (16). These data are consistent with the literature which describes increased cerebral metabolic rate of oxygen (CRMO<sub>2</sub>) post-cardiac surgery (17). An observational study in term neonates with the primary objective of demonstrating CRMO<sub>2</sub>, arterial oxygen content, cerebral blood flow, and cFOE differences due to CPB duration and DHCA, reported increased CRMO<sub>2</sub> [increase of 121% (59-207) from baseline; p = 0.17] and cFOE [increase of 145% (107, 222) from baseline; p = 0.005] 12 h after returning from the operating room (17). Taking these findings together, this may suggest that we should not target CrO<sub>2</sub> above baseline after surgical correction. Of note, in the current study, only one patient underwent DHCA, which is associated with decreased CRMO and cFOE

#### **TABLE 2** | Summary of cardiac diagnosis and surgical procedures (N = 21).

| Patient | Cardiac lesions   | Surgical procedures  | Corrective | Survived |
|---------|---|--|------------|----------|
| 1       | Pulmonary atresia with ventricular septal defect, major<br>aortopulmonary collaterals, left lower pulmonary artery stenosis                           | Repair of pulmonary artery stenosis (left main pulmonary artery to left lower pulmonary artery graft)  | No         | Yes      |
| 2       | Hypoplastic right ventricle, large atrial and ventricular septal defect, transposition of the great arteries  | Fontan procedure   | Yes        | Yes      |
| 3       | Tetralogy of Fallot   | Total repair   | Yes        | Yes      |
| 4       | Pulmonary atresia with ventricular septal defect  | Right ventricle to pulmonary artery conduit<br>Ventricular septal defect repair  | Yes        | Yes      |
| 5       | Tetralogy of Fallot   | Total repair   | Yes        | Yes      |
| 7       | Tetralogy of Fallot   | Total repair   | Yes        | Yes      |
| 8       | Dextrocardia, hypoplastic right ventricle, transposition of the great arteries, severe pulmonary stenosis, moderate atrial septal defect              | Fontan procedure   | Yes        | Yes      |
| 9       | Tetralogy of Fallot   | Total repair   | Yes        | Yes      |
| 10      | Tetralogy of Fallot   | Total repair   | Yes        | Yes      |
| 11      | Pulmonary atresia intact ventricular septum, patent ductus arteriosus   | Right ventricular outflow tract augmentation<br>Ligation of patent ductus arteriosus   | Yes        | Yes      |
| 12      | Complete atrioventricular septal defect, hypoplastic aorta, coarctation of the aorta  | Coarctation repair within 30 days  | No         | Yes      |
| 13      | Pulmonary atresia with intact ventricular septum, moderate mitral regurgitation   | Fontan procedure<br>Mitral annuloplasty  | Yes        | Yes      |
| 14      | Congenitally corrected transposition of the great arteries, large ventricular septal defect, severe pulmonary stenosis                                | Right ventricle to pulmonary artery conduit<br>Ventricular septal defect repair  | Yes        | Yes      |
| 15      | Tetralogy of Fallot   | Total repair   | Yes        | Yes      |
| 16      | Complete atrioventricular septal defect with moderate to severe<br>atrioventricular valve regurgitation, total anomalous pulmonary<br>venous drainage | Repair of complete atrioventricular canal<br>Repair of total anomalous pulmonary venous drainage   | Yes        | No       |
| 17      | Tricuspid valve atresia, hypoplastic right ventricle, ventricular septal defect   | Bidirectional Glenn  | No         | Yes      |
| 18      | Atrioventricular septal defect, hypoplastic right ventricle, pulmonary atresia, major aortopulmonary collaterals                                      | Unifocalization for pulmonary atresia (right lower and middle<br>major aortopulmonary collateral artery unifocalization)<br>Systemic to pulmonary artery shunt (modified Blalock Taussig<br>shunt) | No         | No       |
| 19      | Tetralogy of Fallot   | Total repair   | Yes        | Yes      |
| 20      | Hypoplastic right ventricle, large ventricular septal defect, pulmonary stenosis, transposition of the great arteries                                 | Bidirectional Glenn  | No         | Yes      |
| 21      | Hypoplastic left heart syndrome, partial anomalous pulmonary venous drainage  | Stage 1 repair of hypoplastic left heart syndrome (Norwood operation)  | No         | No       |
| 22      | Double outlet right ventricle-Tetralogy of Fallot type  | Repair of double outlet right ventricle  | Yes        | Yes      |

(18). Moreover, this patient died and did not contribute to hospital discharge  $CrO_2$  data. To the best of our knowledge, there are no studies describing cFOE trends in the postoperative period beyond the first postoperative day in children with CHD. As we were not able to measure cFOE directly, future studies describing these values in children undergoing cardiac surgery would be required to describe this physiological response in greater detail.

Baseline  $\text{CrO}_2$  and  $\text{SrO}_2$  in our cohort were 63.8 (57.2, 76.6) and 74.6% (68.9, 82.4), respectively. These values are relatively high compared to other studies involving children with cyanotic CHD. A large prospective study (n = 112) reported different baseline  $\text{CrO}_2$  with different diagnosis: tetralogy of Fallot (57 ± 12), pulmonary atresia (38 ± 6), single ventricle with aortopulmonary

shunt (50  $\pm$  7), bidirectional cavo-pulmonary connection (43  $\pm$  6), and Fontan (70  $\pm$  4). All patients except those in the Fontan group had CrO<sub>2</sub> lower than the control group of healthy patients (68  $\pm$  10) (10). In staged surgery for single-ventricle physiology, patients had a baseline CrO<sub>2</sub> of 61% at pre-stage 1, 48% post-stage 1, CrO<sub>2</sub> of 42% pre-stage 2, 53% post-stage 2, and CrO<sub>2</sub> of 70% pre-Fontan which remained the same after completion of the Fontan procedure (11). We postulate the reason for the high baseline in our study is because the majority of our patients had their baseline (pre-CPB) taken a few minutes after intubation and ventilation. Patients in this cohort were mostly toddlers and young children who were uncooperative for placement of NIRS sensors prior to anesthesia. Hence, we postulate the high baseline tissue oximetry readings were because the patients were already

#### **TABLE 3** | Summary of intensive care unit (ICU) variables (N = 21).

| ICU variables                 | Corre                  | ective surgery (N = 15) |         | Non-correc                     | ctive surgery ( $N = 6$ )      |                 |
|-------------------------------|------------------------|-------------------------|---------|--------------------------------|--------------------------------|-----------------|
|                               | Day 1 ( <i>N</i> = 15) | Day 2 (N = 12)          | p-value | Day 1 ( <i>N</i> = 6)          | Day 2 (N = 3)                  | <i>p</i> -value |
| Toe-core gap, °C              | 6.2 (4.0, 8.2)         | 6.7 (4.3, 7.8)          | 0.470   | 2.8 (2.8, 3.0)                 | 5.8 (3.7, 8.0)                 | 1.000           |
| Central venous pressure, mmHg | 12.3 (11.2, 13.0)      | 14.0 (8.0, 15.3)        | 0.278   | 8.5 (6.0, 10.4)                | 11.5 (9.3, 19.9)               | 0.500           |
| Lactate, mmol/L               | 2.7 (2.3, 5.0)         | 1.9 (1.4, 3.7)          | 0.193   | 2.4 (1.3, 5.5)                 | 2.0 (1.1, 3.8)                 | 0.250           |
| Hemoglobin, g/dL              | 13.0 (12.2, 14.5)      | 11.5 (10.7, 13.6)       | 0.148   | 11.6 (10.7, 12.6)              | 12.9 (10.1, 14.0)              | 1.000           |
| Urine output, ml/kg/h         | 0.8 (0.6, 1.5)         | 1.1 (0.9, 2.2)          | 0.077   | 1.8 (1.1, 2.0)                 | 1.2 (0.3, 4.1)                 | 1.000           |
| Cumulative balance, ml/kg     | 0.5 (-9.1, 10.9)       | 0.6 (-4.3, 19.1)        | 0.791   | 4.3 (-0.1, 115.7) <sup>a</sup> | 93.7 (4.8, 130.5) <sup>a</sup> | 1.000           |
| Postoperative inotrope        |                        |                         |         |                                |                                |                 |
| Dopamine                      | 0 (0.0)                | 0 (0.0)                 | -       | 1 (16.7)                       | 1 (33.3)                       | 1.000           |
| Adrenaline                    | 14 (93.3)              | 6 (50.0)                | 0.024   | 3 (50.0)                       | 2 (66.7)                       | 1.000           |
| Noradrenaline                 | 2 (13.3)               | 3 (5.0)                 | 0.628   | 1 (16.7)                       | 2 (66.7)                       | 0.226           |
| Milrinone                     | 15 (100.0)             | 10 (83.3)               | 0.188   | 3 (50.0)                       | 2 (66.7)                       | 1.000           |
| Phentolamine                  | 0 (0.0)                | 0 (0.0)                 | -       | 1 (16.7)                       | 1 (33.3)                       | 1.000           |
| Ventilation variables         |                        |                         |         |                                |                                |                 |
| PIP, cm H₂O                   | 17.2 (13.2, 19.3)      | 20.6 (19.0, 21.3)       | 0.688   | 18.0 (16.9, 20.3)              | 20.0 (18.0, 22.0)              | 1.000           |
| PEEP, cm H <sub>2</sub> O     | 5.0 (5.0, 6.0)         | 6.3 (5.0, 7.0)          | 1.000   | 6.5 (5.0, 8.5)                 | 8.0 (5.0, 10.0)                | 1.000           |
| MAP, cm H <sub>2</sub> O      | 8.5 (7.4, 9.8)         | 10.9 (10.3, 11.4)       | 0.438   | 8.9 (8.5, 10.8)                | 10.4 (8.8, 12.0)               | 0.500           |
| TV, mL/kg                     | 7.9 (6.8,10.2)         | 6.6 (6.3, 6.8)          | 0.156   | 6.0 (4.1, 7.5)                 | 3.7 (2.2, 5.1)                 | 1.000           |
| FiO <sub>2</sub> , %          | 0.4 (0.3, 0.7)         | 0.4 (0.3, 0.5)          | 0.734   | 0.3 (0.2, 0.4)                 | 0.2 (0.2, 0.3)                 | 0.500           |
| SpO <sub>2</sub> , %          | 97 (95, 98)            | 98 (89, 99)             | 0.266   | 80 (77, 92)                    | 90 (70, 98)                    | 0.250           |
| Inhaled nitric oxide          | 1 (6.7)                | 1 (8.3)                 | 1.000   | 0 (0.0)                        | 0 (0.0)                        | -               |
| Blood gas variables           |                        |                         |         |                                |                                |                 |
| рН                            | 7.4 (7.4, 7.4)         | 7.4 (7.4, 7.4)          | 0.966   | 7.4 (7.3, 7.4)                 | 7.4 (7.3, 7.4)                 | 0.500           |
| PaO <sub>2</sub> , mmHg       | 95.0 (65.8, 104.7)     | 93.7 (52.9, 117.6)      | 0.898   | 48.6 (44.4, 50.8)              | 77.2 (48.0, 100.1)             | 0.750           |
| PaCO <sub>2</sub> , mmHg      | 39.1 (34.8, 40.8)      | 37.5 (34.6, 39.6)       | 0.520   | 44.4 (42.2, 48.1)              | 41.8 (39.8, 46.2)              | 0.250           |
| HCO <sub>3</sub> , mmol/L     | 22.8 (21.8, 23.4)      | 22.6 (21.5, 23.3)       | 0.465   | 24.0 (22.0, 25.5)              | 23.8 (20.0, 27.5)              | 1.000           |
| Base deficit                  | -2.3 (-3.6, -1.6)      | -2.9 (-4.1, -2.0)       | 0.365   | -0.1 (-2.8, 0.9)               | -1.3 (-5.0, 4.3)               | 1.000           |
|                               | ,                      |                         |         |                                | /                              |                 |

Categorical and continuous variables presented as counts (percentages) and median (interquartile range), respectively.

<sup>a</sup>High third quartile due to two patients (number 18 and 21) with high cumulative positive balance.

PIP, peak inspiratory pressure; PEEP, positive end expiratory pressure; MAP, mean airway pressure; TV, tidal volume; FiO<sub>2</sub>, fraction of inspired oxygen; SpO<sub>2</sub>, pulse oximetry; PaO<sub>2</sub>, partial pressure of arterial oxygen; PaCO<sub>2</sub>, partial pressure of carbon dioxide; HCO<sub>3</sub>, bicarbonate.

Bold value represents p < 0.05.

TABLE 4 | Significant postoperative hemodynamic events and interventions within first 2 postoperative days.

|                              | Corr                                      | ective surgery ( $N = 15$ )               |         | Non-c                                    | orrective surgery ( $N = 0$              | 6)              |
|------------------------------|---|---|---------|--|--|-----------------|
|                              | Day 1 ( <i>N</i> = 15)<br><i>n</i> (%) nE | Day 2 ( <i>N</i> = 12)<br><i>n</i> (%) nE | p-value | Day 1 ( <i>N</i> = 6)<br><i>n</i> (%) nE | Day 2 ( <i>N</i> = 3)<br><i>n</i> (%) nE | <i>p</i> -value |
| Hemodynamic events           |   |   |         |  |  |                 |
| Hypotension                  | 11 (73.3) 62                              | 5 (41.7) 53                               | 0.130   | 3 (50.0) 47                              | 2 (66.7) 33                              | 1.000           |
| Desaturation                 | 1 (6.7) 1                                 | 1 (8.3) 1                                 | 1.000   | 2 (33.3) 10                              | 1 (33.3) 21                              | 1.000           |
| Cannula dislodgement         | 1 (6.7) 17                                | 0 (0.0) 0                                 | 1.000   | 1 (16.7) 1                               | 1 (33.3) 1                               | 1.000           |
| Arrhythmia                   | 7 (46.7) 54                               | 4 (33.3) 41                               | 0.696   | 1 (16.7) 17                              | 0 (0.0) 0                                | 1.000           |
| Cardiac arrest               | 0 (0.0) 0                                 | 0 (0.0) 0                                 | -       | 0 (0.0) 0                                | 0 (0.0) 0                                | -               |
| Hemorrhage                   | 3 (20.0) 9                                | 2 (16.7) 3                                | 1.000   | 0 (0.0) 0                                | 0 (0.0) 0                                | -               |
| Oliguria                     | 1 (6.7) 2                                 | 0 (0.0) 0                                 | 1.000   | 0 (0.0) 0                                | 0 (0.0) 0                                | -               |
| Interventions                |   |   |         |  |  |                 |
| Fluid bolus                  | 12 (80.0) 51                              | 4 (33.3) 21                               | 0.022   | 2 (33.3) 17                              | 1 (33.3) 5                               | 1.000           |
| Transfusion                  | 5 (33.3) 19                               | 2 (16.7) 3                                | 0.408   | 3 (50.0) 31                              | 2 (66.7) 13                              | 1.000           |
| Increase inotrope            | 3 (20.0) 6                                | 3 (25.0) 4                                | 1.000   | 1 (16.7) 2                               | 2 (66.7) 7                               | 0.226           |
| Cardiac massage              | 0 (0.0) 0                                 | 0 (0.0) 0                                 | -       | 0 (0.0) 0                                | 0 (0.0) 0                                | -               |
| Defirbillation/cardioversion | 0 (0.0) 0                                 | 0 (0.0) 0                                 | -       | 0 (0.0) 0                                | 0 (0.0) 0                                | -               |
| ECMO                         | 0 (0.0) 0                                 | 0 (0.0) 0                                 | -       | 1 (16.7) 25                              | 1 (33.3) 24                              | 1.000           |
| Amiodarone                   | 1 (6.7) 1                                 | 1 (8.3) 11                                | 1.000   | 0 (0.0) 0                                | 1 (33.3) 1                               | 0.333           |
| Chest toilet                 | 1 (6.7) 1                                 | 0 (0.0) 0                                 | 1.000   | 0 (0.0) 0                                | 0 (0.0) 0                                | -               |
| Pacing                       | 3 (20.0) 28                               | 2 (16.7) 25                               | 1.000   | 1 (16.7) 8                               | 0 (0.0) 0                                | 1.000           |

Categorical and continuous variables presented as counts (percentages) and median (interquartile range), respectively.

ECMO, extracorporeal membrane oxygenation; n, number of subjects (% = percent of subjects); nE, total number events.

Bold value represents p < 0.05.

|                      |                         |   | Time                 | period            |                   |                   |        | <i>p</i> -value (co | mpared to p | re-CPB) |           |
|----------------------|-------------------------|---|----------------------|-------------------|-------------------|-------------------|--------|---------------------|-------------|---------|-----------|
|                      |                         | СРВ   |                      | 2                 | n                 | Discharge         | СР     | m                   | Ū           | _       | Discharge |
|                      | Pre                     | During  | Post                 | Day 1             | Day 2             |                   | During | Post                | Day 1       | Day 2   |           |
| Corrective sui       | gery                    |   |                      |                   |                   |                   |        |                     |             |         |           |
| SpO <sub>2</sub> (%) | 86 (79, 90)             | 99 (94, 100)  | 99 (98, 100)         | 97 (95, 98)       | 98 (89, 99)       | 97 (92, 98)       | 0.004  | <0.001              | <0.001      | <0.001  | <0.001    |
| Cerebral (%)         | 72.1 (63.0, 78.3)       | 69.2 (61.2, 74.7)                                       | 72.8 (58.8, 79.0)    | 66.4 (61.2, 75.1) | 68.3 (55.0, 74.4) | 60.5 (53.6, 62.9) | 0.761  | 0.761               | 0.135       | 0.520   | 0.005     |
| Somatic (%)          | 72.7 (65.6, 77.3)       | 86.3 (83.6, 88.6)                                       | 87.3 (77.2, 89.5)    | 72.5 (68.1, 79.3) | 71.9 (63.4, 74.1) | 66.9 (57.3, 76.9) | <0.001 | <0.001              | 0.890       | 0.339   | 0.048     |
| Non-correctiv        | e surgery               |   |                      |                   |                   |                   |        |                     |             |         |           |
| SpO <sub>2</sub> (%) | 87 (79, 90)             | 95 (95, 95)   | 82 (82, 86)          | 80 (77, 92)       | 90 (70, 98)       | 80 (80, 81)       | 1.000  | 0.250               | 0.875       | 1.000   | 0.250     |
| Cerebral (%)         | 59.4 (42.5, 65.8)       | 73.8 (66.0, 77.8)                                       | 58.8 (52.9, 67.7)    | 54.1 (46.4, 66.0) | 64.4 (36.2, 66.6) | 54.5 (52.9, 60.4) | 0.125  | 0.875               | 0.875       | 1.000   | 0.250     |
| Somatic (%)          | 64.6 (42.8, 74.7)       | 81.4 (74.1, 91.1)                                       | 79.2 (58.9, 84.1)    | 69.8 (60.4, 71.7) | 65.3 (48.2, 66.1) | 56.9 (50.3, 60.6) | 0.125  | 0.125               | 0.625       | 0.500   | 0.250     |
| Continuous varié     | bles are presented as n | median (interquartile range<br>ansive care unit: SoO pr | 3).<br>Ilsa ovimatov |                   |                   |                   |        |                     |             |         |           |

sedated, intubated, and ventilated, and this may lead to increase in  $CrO_2$  and  $SrO_2$  readings (19, 20).

A retrospective study (n = 25) of infants undergoing elective cardiac surgery showed that CrO2 was always lower than that of other regions (including renal, arm, and thigh) (21). This reflects a higher FOE across the cerebral bed compared with the somatic bed (22). We observed a similar phenomenon in our cohort, and this supports the use of CrO<sub>2</sub> as the main site for regional oximetry monitoring in the most vulnerable of patients. These patients while on CPB also showed a higher CrO<sub>2</sub> and SrO<sub>2</sub> compared to other perioperative time-points. This increase associated with CPB was observed regardless of anatomical diagnosis (10, 11, 23). In our study, we noted that there was an increase in both cerebral and SrO<sub>2</sub> sites for on CPB. SrO<sub>2</sub> was higher during CPB compared to pre-CPB [86.3 (83.6, 88.6) vs. 72.7% (65.6, 77.3); p < 0.001]. This effect normalized after coming off CPB. It is suggested that the marked increase in SrO<sub>2</sub> site (above normal levels) is due to over-oxygenation or reduced oxygen consumption at these sites (21).

A trend of declining  $SrO_2$  is observed over the first 48 h as the patient recovers from surgery in the PICU. Although we were not able to elicit the exact reasons for this phenomenon in this study, this decreasing trend may be explained by factors that affect  $CrO_2$  and  $SrO_2$  such as increased oxygen demand after surgery as the patient is weaned from sedation and ventilation, low cardiac output states, hypovolemia, microcirculatory disturbance, increased vascular tone, and changes in the toe-core temperature gap (5, 19, 20). However, the lack of decline in  $CrO_2$  values may be related to the preservation of cerebral autoregulation (24, 25).

There was a decrease in both  $CrO_2$  and  $SrO_2$  at hospital discharge compared to baseline in both the corrective and palliative surgery groups, but it did not reach statistical significance for the latter possibly due to the small sample size. The oximetry readings taken at hospital discharge spanned 4–6 h during overnight sleep when the patient was considered well and fit for home. It is likely the  $CrO_2$  and  $SrO_2$  at hospital discharge reflects the true baseline and the pre-CPB values reflect a hyperoxygenated state as it was taken with the patient on mechanical ventilation.

Although this is a pilot and purely descriptive study, to the best of our knowledge, this is the first study to longitudinally examine NIRS perioperatively up to hospital discharge in children with cyanotic CHD undergoing surgical correction. We demonstrated that CrO<sub>2</sub> and SrO<sub>2</sub> did not show a sustained increase even up until the time of hospital discharge in patients who had undergone complete repair. Hence, our findings potentially imply that during the postoperative period, oximetry values may not be necessarily higher than baseline even when SpO<sub>2</sub> completely normalizes. Even though our sample size was small, we managed to achieve our aim of describing the postoperative CrO<sub>2</sub> and SrO<sub>2</sub> values beyond 24 h after surgery. However, due to the small sample size we were not able to meaningfully stratify CrO<sub>2</sub> and SrO<sub>2</sub> according to baseline characteristics (e.g., age, type of procedure). Another factor may have limited our analysis was that our patients were young and too fretful to have the NIRS sensors placed pre-induction of anesthesia. Most of these sensors were placed after sedation and successful intubation, leading to higher baseline oximetry than expected. Another limitation is the wide

**IABLE 5** | SpO<sub>2</sub>, cerebral, and somatic tissue oxygenation measurements throughout the perioperative period.







limits of agreement between one cerebral oximeter and another, making devices non-interchangeable and hence, the results of this study may not be generalized to all makes of the cerebral oximeter (26). Finally, we were not able to obtain NIRS value during longer follow-up period such as 3–6 months after surgery, as we focused our study on the immediate perioperative period.

In conclusion, this pilot study demonstrated that  $SpO_2$  normalizes immediately after surgery but  $CrO_2$  and  $SrO_2$  does not show a sustained increase after surgical correction of cyanotic CHD even up to the time of hospital discharge. Future larger studies are required to validate our findings so as to inform future guidelines and management algorithms using NIRS in this group of children.

### ETHICS STATEMENT

This study was carried out in accordance with the recommendations of the SingHealth Centralised Institutional Review Board (reference number: 2015/2161). The study protocol was approved by the SingHealth Centralised Institutional Review Board. The

# REFERENCES

 Ghanayem NS, Hoffman GM. Near infrared spectroscopy as a hemodynamic monitor in critical illness. *Pediatr Crit Care Med* (2016) 17(8 Suppl 1):S201–6. doi:10.1097/PCC.000000000000780 legal representative of all subjects gave written informed consent in accordance with the Declaration of Helsinki.

# **AUTHOR CONTRIBUTIONS**

JW, CC, RM, OW, TT, MN, JA, TL, and JL contributed conception and design of the study; RM and JA performed the statistical analysis; JW and JL wrote the first draft of the manuscript; CC, OW, TT, and MN wrote sections of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.

### ACKNOWLEDGMENTS

The authors thank Ms. Kathy Liaw Chiew Suan and Ms. Chen Su Qiu (clinical research coordinators) for assisting with patient recruitment and ensuring protocol adherence. The authors also thank the patients and parents who agreed to participate in this study.

- Gregory A, Kohl BA. Con: near-infrared spectroscopy has not proven its clinical utility as a standard monitor in cardiac surgery. J Cardiothorac Vasc Anesth (2013) 27(2):390–4. doi:10.1053/j.jvca.2012.11.010
- 3. Hoskote AU, Tume LN, Trieschmann U, Menzel C, Cogo P, Brown KL, et al. A cross-sectional survey of near-infrared spectroscopy use in pediatric cardiac

ICUs in the United Kingdom, Ireland, Italy, and Germany. *Pediatr Crit Care Med* (2016) 17(1):36–44. doi:10.1097/PCC.00000000000564

- McQuillen PS, Nishimoto MS, Bottrell CL, Fineman LD, Hamrick SE, Glidden DV, et al. Regional and central venous oxygen saturation monitoring following pediatric cardiac surgery: concordance and association with clinical variables. *Pediatr Crit Care Med* (2007) 8(2):154–60. doi:10.1097/01. PCC.0000257101.37171.BE
- Chakravarti SB, Mittnacht AJ, Katz JC, Nguyen K, Joashi U, Srivastava S. Multisite near-infrared spectroscopy predicts elevated blood lactate level in children after cardiac surgery. J Cardiothorac Vasc Anesth (2009) 23(5):663–7. doi:10.1053/j.jvca.2009.03.014
- Daubeney PE, Pilkington SN, Janke E, Charlton GA, Smith DC, Webber SA. Cerebral oxygenation measured by near-infrared spectroscopy: comparison with jugular bulb oximetry. *Ann Thorac Surg* (1996) 61(3):930–4. doi:10.1016/ 0003-4975(95)01186-2
- Kussman BD, Wypij D, Laussen PC, Soul JS, Bellinger DC, DiNardo JA, et al. Relationship of intraoperative cerebral oxygen saturation to neurodevelopmental outcome and brain magnetic resonance imaging at 1 year of age in infants undergoing biventricular repair. *Circulation* (2010) 122(3):245–54. doi:10.1161/CIRCULATIONAHA.109.902338
- Sood ED, Benzaquen JS, Davies RR, Woodford E, Pizarro C. Predictive value of perioperative near-infrared spectroscopy for neurodevelopmental outcomes after cardiac surgery in infancy. *J Thorac Cardiovasc Surg* (2013) 145(2):438–45.e1; discussion 44–5. doi:10.1016/j.jtcvs.2012. 10.033
- Bhalala US, Nishisaki A, McQueen D, Bird GL, Morrison WE, Nadkarni VM, et al. Change in regional (somatic) near-infrared spectroscopy is not a useful indicator of clinically detectable low cardiac output in children after surgery for congenital heart defects. *Pediatr Crit Care Med* (2012) 13(5):529–34. doi:10.1097/PCC.0b013e3182389531
- Kurth CD, Steven JL, Montenegro LM, Watzman HM, Gaynor JW, Spray TL, et al. Cerebral oxygen saturation before congenital heart surgery. *Ann Thorac Surg* (2001) 72(1):187–92. doi:10.1016/S0003-4975(01)02632-7
- Fenton KN, Freeman K, Glogowski K, Fogg S, Duncan KF. The significance of baseline cerebral oxygen saturation in children undergoing congenital heart surgery. *Am J Surg* (2005) 190(2):260–3. doi:10.1016/j.amjsurg.2005. 05.023
- Tume LN, Arnold P. Near-infrared spectroscopy after high-risk congenital heart surgery in the paediatric intensive care unit. *Cardiol Young* (2015) 25(3):459–67. doi:10.1017/S1047951114000055
- Kellum JA, Bellomo R, Ronco C. The concept of acute kidney injury and the RIFLE criteria. *Contrib Nephrol* (2007) 156:10–6. doi:10.1159/000102010
- Thorniley MS, Livera LN, Wickramasinghe YA, Spencer SA, Rolfe P. The non-invasive monitoring of cerebral tissue oxygenation. *Adv Exp Med Biol* (1990) 277:323–34. doi:10.1007/978-1-4684-8181-5\_38
- Kussman BD, Laussen PC, Benni PB, McGowan FX Jr, McElhinney DB. Cerebral oxygen saturation in children with congenital heart disease and chronic hypoxemia. *Anesth Analg* (2017) 125(1):234–40. doi:10.1213/ANE. 000000000002073
- Wardle SP, Yoxall CW, Weindling AM. Determinants of cerebral fractional oxygen extraction using near infrared spectroscopy in preterm neonates.

J Cereb Blood Flow Metab (2000) 20(2):272-9. doi:10.1097/00004647-200002000-00008

- Buckley EM, Lynch JM, Goff DA, Schwab PJ, Baker WB, Durduran T, et al. Early postoperative changes in cerebral oxygen metabolism following neonatal cardiac surgery: effects of surgical duration. *J Thorac Cardiovasc Surg* (2013) 145(1):196.e–205.e. doi:10.1016/j.jtcvs.2012.09.057
- Greeley WJ, Kern FH, Ungerleider RM, Boyd JL III, Quill T, Smith LR, et al. The effect of hypothermic cardiopulmonary bypass and total circulatory arrest on cerebral metabolism in neonates, infants, and children. *J Thorac Cardiovasc Surg* (1991) 101(5):783–94.
- Fleck T, Schubert S, Ewert P, Stiller B, Nagdyman N, Berger F. Propofol effect on cerebral oxygenation in children with congenital heart disease. *Pediatr Cardiol* (2015) 36(3):543–9. doi:10.1007/s00246-014-1047-7
- Booth EA, Dukatz C, Sood BG, Wider M. Near-infrared spectroscopy monitoring of cerebral oxygen during assisted ventilation. *Surg Neurol Int* (2011) 2:65. doi:10.4103/2152-7806.81722
- Ricci Z, Haiberger R, Tofani L, Romagnoli S, Favia I, Cogo P. Multisite near infrared spectroscopy during cardiopulmonary bypass in pediatric patients. *Artif Organs* (2015) 39(7):584–90. doi:10.1111/aor.12424
- Ghanayem NS, Wernovsky G, Hoffman GM. Near-infrared spectroscopy as a hemodynamic monitor in critical illness. *Pediatr Crit Care Med* (2011) 12 (4 Suppl):S27–32. doi:10.1097/PCC.0b013e318221173a
- Daubeney PE, Smith DC, Pilkington SN, Lamb RK, Monro JL, Tsang VT, et al. Cerebral oxygenation during paediatric cardiac surgery: identification of vulnerable periods using near infrared spectroscopy. *Eur J Cardiothorac Surg* (1998) 13(4):370–7. doi:10.1016/S1010-7940(98)00024-4
- Brady KM, Mytar JO, Lee JK, Cameron DE, Vricella LA, Thompson WR, et al. Monitoring cerebral blood flow pressure autoregulation in pediatric patients during cardiac surgery. *Stroke* (2010) 41(9):1957–62. doi:10.1161/ STROKEAHA.109.575167
- Vretzakis G, Georgopoulou S, Stamoulis K, Stamatiou G, Tsakiridis K, Zarogoulidis P, et al. Cerebral oximetry in cardiac anesthesia. J Thorac Dis (2014) 6(Suppl 1):S60–9. doi:10.3978/j.issn.2072-1439.2013.10.22
- Pisano A, Galdieri N, Iovino TP, Angelone M, Corcione A. Direct comparison between cerebral oximetry by INVOS(TM) and EQUANOX(TM) during cardiac surgery: a pilot study. *Heart Lung Vessel* (2014) 6(3):197–203.

**Conflict of Interest Statement:** This study was investigator initiated but funded by Medtronic including the provision of the Somanetics NIRs device, neonatal, pediatric sensors, and the software necessary to conduct this study. JL is the principal investigator for the grant awarded by Medtronic for the conduct of this study (Project ID: ISR-2014-10423). Medtronic staff was not involved in the study design, execution, and analysis of the results.

Copyright © 2018 Wong, Chen, Moorakonda, Wijeweera, Tan, Nakao, Allen, Loh and Lee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.